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Abstract
Objectives Cervical cancer is the most common malig-
nant tumor in female reproductive tract and primarily
metastasizes through the lymphatic system that will affect
prognosis of patients. Maspin, a member of the serine
protease inhibitors (serpins) super family, has recently been
indicated as a tumor suppressor in many cancers. In this
study, we investigated the clinical significance of maspin
expression, especially the subcellular location of maspin
and its functional role in progression and lymphangiogen-
esis, in cervical squamous cell carcinoma.
Methods Labelled streptavidin biotin method (LSAB) was
used to determine cytoplasmic and nuclear maspin expressions,
respectively, in 13 cases of normal cervix, 15 cases of cervical
intraepithelial neoplasia grade 3 (CIN3), 62 cases of squamous
cell carcinoma (SCC) of the uterine cervix, and 13 cases of
pelvic lymphatic nodes which were all positive lymphatic nodes
in our selected cancer cases. LSAB is also used to detect po-
doplanin which is used for counting density of lymphatic
microvessels (LMVD). The clinical significance of subcellular
maspin expression and the relationship between maspin
expression and LMVD in cervical cancer are analyzed.
Results Both cytoplasmic and nuclear maspin expressions
in SCC were significantly weaker than those of normal cervix
and CIN3. Nuclear maspin expression showed a peak in
CIN3 and then dropped in SCC. Declined maspin expression
was correlated with later clinical stage, increased LMVD,
and lymphatic metastasis.
Conclusions Our results suggest that subcellular location
of maspin expression is a potential predictive factor in
tumor progression and in patients’ prognosis of cervical
cancer, and maspin plays a suppression role in lymphan-
giogenesis and metastasis.
Keywords Cervix  CIN  Maspin  Lymphatic
system  Podoplanin  Squamous cell carcinoma
Abbreviations
CIN3 Cervical intraepithelial neoplasia grade 3
LMVD Density of lymphatic microvessels
SCC Squamous cell carcinoma
Introduction
Maspin is a serine protease inhibitor located at 18q21.3,
along with other serpin genes such as squamous cell
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carcinoma antigens 1 and 2, and PAI-2 [1]. It was identified
in 1994 as a tumor suppressor gene from normal mammary
epithelial cells [2]. Since then, accumulated evidence has
demonstrated its tumor-suppression role [2–7], which was
further enhanced by recent studies that showed downreg-
ulation or loss of maspin expression indicated greater
propensity for metastasis and poor prognosis in patients,
whereas upregulation of maspin is one of the independent
factors for good prognosis [6–9]. Maspin inhibits cell
growth and motility, weakens the potential for invasion and
metastasis [8, 10], and engenders a sensitizing effect on
apoptosis [11]. Nevertheless, despite its declined expres-
sion in many kinds of cancers, maspin was overexpressed
in some other tumors, such as colonic carcinoma, ovarian
carcinoma, and gallbladder cancer [12–15]. New evidence
showed that maspin expression in breast cancer was posi-
tively related to tumor size and histological grade, but
negatively related to relapse-free survival and total survival
spans of patients, which questioned maspin’s role as a
tumor suppressor [10, 16–18]. The paradoxical expressions
of maspin in different types of tumors may provide new
insights regarding the role of maspin in tumor progression,
metastasis and prognosis. Furthermore, a few recent studies
showed that cytoplasmic and nuclear maspin expressions
may predict the different clinical types in prognosis of
patients in ovarian cancer, non-small-cell lung cancer and
laryngocarcinoma [2, 19–21], which suggested that even
further significance may exist in subcellular localization of
maspin.
Carcinoma of the uterine cervix is one of the most
common malignancies in female genital tract in which
lymphatic metastasis is the primary route of spread out and
a cardinal factor for prognosis of patients. Podoplanin is
one of the complete membrane-spanning proteins with
molecular weight 43 Kd that was first discovered in glo-
merular epithelial cells in 1999 [22] and had been proved to
be an ideal specific marker for endothelial cells of lym-
phatic vessels [23].
At present, the molecular and biological mechanisms of
maspin functions are still unclear. Only a few studies have
been performed to determine the maspin expression and its
relationship with angiogenesis and vascular metastasis in
cervical cancer, whereas subcellular location of maspin
expression and its association with lymphangiogenesis and
lymphatic metastasis remains blank. In our study, we
evaluate cytoplasmic and nuclear maspin expression
respectively in normal cervix, cervical intraepithelial neo-
plasia grade 3 (CIN3) and squamous cell carcinoma (SCC)
of the uterine cervix and the density of lymphatic micro-
vessels (LMVD) in the tumor tissue to discover the rela-
tionship between maspin subcellular expression and
progression as well as lymphangiogenesis and lymphatic
metastasis in cervical cancer.
Methods
Tissue samples
We conducted a retrospective study of maspin expression.
A total of 13 cases of normal cervix which were all leio-
myoma of the uterus, 15 cases of CIN3, 62 cases of SCC of
the uterine cervix, and 13 cases of pelvic lymphatic nodes,
which were all positive lymphatic nodes in our selected
cancer cases from the period October, 2004 to April, 2006
were retrieved from the archival files of the Department of
Pathology, West China Second Hospital of Sichuan Uni-
versity. No patient of cervical cancer has received radio-
therapy, chemotherapy and biotherapy preoperatively. The
pathologic diagnosis was definitely postoperative, which
was reviewed by two experienced pathologists, and both
the clinical and the pathologic data were complete. The
clinical stage of cervical cancer was defined according to
the criteria set forth by International Federal of Obstetrics
and Gynecology (FIGO) in 2000. The whole study received
permission from the ethics committees of China.
Immunohistochemistry methods
Both maspin and podoplanin expressions were detected by
labelled streptavidin biotin method (LSAB). Formalin-
fixed, paraffin-embedded tissue blocks were sectioned at
4 lm intervals in four pieces, which were mounted on
glasses with APES prime coat, baked under 60 C for 3 h
and turned to constant temperature in an oven at 37 C for
48 h. Deparaffinized in xylol third for 10 min each, and
hydrated gradually through graded alcohols (100 %, 95 %,
80 % and 70 % ethanol each for once). To enhance the
immunostaining, an antigen retrieval procedure was per-
formed. The deparaffinized maspin sections were placed in
an autoclave sterilizer filled with 0.01 M citrate buffer
solution pH 6.0, steamed for 4 min, and then washed with
PBS (pH 7.2) third after natural cooling. The podoplanin
sections were placed in a microwave oven in high gear
filled with 0.01 M citrate buffer solution pH 6.0 for 5 min
and then in middle gear for 10 min and washed with PBS
(pH 7.2) third for 5 min each after natural cooling under
room temperature. The sections were sequentially incu-
bated in goat blocking serum in PBS, 1:500 dilutions of
monoclonal maspin antibody (NeoMarkers, CA, USA), or
1:100 dilutions of polyclonal podoplanin antibody (AbD
Serotec, UK), biotinylated secondary antibody IgG, and
avidin-biotinylated peroxidase. After a final wash with
PBS, chromogenic detection and hematoxylin counterstain
were performed.
Positive and negative controls were set. Maspin
expression took normal breast tissue and podoplanin took
lymphatic nodes as positive controls while two first
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antibodies replaced with PBS respectively were taken as
negative controls.
Results determination
Characteristic cytoplasmic and nuclear granular staining of
yellow or yellow brown is considered positive and the
immunoreactivity was scored using a scale of 0 to 3 based
on the percentage of positive cells, intensity of staining and
heterogeneity of staining [1].
Two pathologists (KX Y, SH W) reviewed the slides
independently to evaluate the maspin expression. Four
high-power fields (9400) were chosen in each slide to
evaluate cytoplasmic and nuclear maspin expressions,
respectively.
For assessing LMVD, the reports of Weidner [24] and
Jackson [25] were consulted for vessel counting. First, scan
the whole section under low-power field (940) and choose
four fields of high-density area of lymphatic microvessels
called ‘‘hot spot’’ to count the number under high-power
field (9400). The mean number of lymphatic microvessels
of the four fields was taken as the result. Vessels which
contained more than eight endothelial cells or smooth
muscles were not counted.
Statistical analysis
The sums of scores from different test groups of maspin
expression were statistically compared using the Kruskal–
Wallis rank sum test. Maspin expression, density of LMVD
and clinical or pathologic parameters were compared using
the logistic regression analysis while the correlation among
the group of SCC. All patients of SCC were free of them in
SCC were analyzed using the Spearman rank correlation
analysis, t test and Mann–Whitney rank test.
Results
The range and mean age of patients in each group is shown
in (Table 1). There are 49 premenopausal and 13 post-
menopausal patients, respectively, in the SCC group. All
patients of SCC were free of radiotherapy and chemo-
therapy, preoperatively.
Among 62 patients of SCC, there are 15 stage Ib and 47
stage II. For histological grade, 17 patients were high to
moderate differentiation and 45 were poor differentiation.
There were 13 cases of local lymphatic metastasis, and the
other 49 cases were free of it. Invasive depth of interstitial
and muscular layer is less than 1/2 in 14 cases and more or
equal to 1/2 in 48 cases according to the pathologic reports,
postoperatively.
Maspin expression and subcellular localization
in normal cervix, CIN3 and SCC
Maspin expression was detected in both cytoplasm and
nucleus of squamous epithelium cells of normal cervix,
CIN3 and SCC of the uterine cervix while no maspin
expressed in the lymph nodes free of tumor metastasis.
Cytoplasm and nucleus of squamous epithelial cells in
normal cervix and CIN3 exhibited moderate to strong
maspin expression while SCC showed obviously weaker
staining for maspin (P \ 0.05) and tumor emboli in lymph
nodes was the weakest (P \ 0.05) (Figs. 1, 2, 3, 4, 5, 6).
Squamous cell carcinoma stage Ib cytoplasmic maspin
showed no significant difference with SCC stage II
(P [ 0.05), but weaker than normal cervix and CIN3
(P \ 0.05). In cytoplasm of tumor emboli in lymph nodes,
maspin expression was obviously weaker than that of SCC
stage II (P \ 0.05) (Table 2). Compared with normal cer-
vix, nuclear maspin expression of CIN3 was little up-reg-
ulated whereas that of SCC stage Ib was declined
(P [ 0.05) which was significantly weaker than CIN3
(P \ 0.05). SCC stage II nuclear maspin was obviously
weaker than SCC stage Ib (P \ 0.05) but showed no








(myoma of the uterus)
33–52 39.78 ± 8.56 13
CIN3 28–55 40.56 ± 7.26 15
SCC 27–74 42.78 ± 12.64 62
SCC with lymphatic
nodes metastasis
34–62 44.37 ± 9.52 13
SCC Squamous cell carcinoma
Fig. 1 This figure shows maspin expression in squamous epithelium of
normal cervix. Both cytoplasm and nucleus of squamous epithelial cells in
normal cervix exhibited moderate to strong maspin expression (HE9400)
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statistical significance with tumor emboli in lymph nodes
(P [ 0.05) probably due to the number of cases with tumor
emboli in lymph nodes (Table 3).
Podoplanin expression in SCC
Positive expression of podoplanin was deposition of yellow
or brown particles in cytoplasm of endothelial cells of
lymphatic vessels. The ‘‘hot spot’’ of lymphatic micro-
vessels were mostly located in tumor interstitial tissues and
periphery but rare or even absent in the internal parts of
tumor (Figs. 7, 8). LMVD in SCC stage Ib and SCC stage
II were 4.47 ± 1.73 and 6.26 ± 1.51 respectively which
were significantly different (P \ 0.05).
Relationship among maspin expression, clinical
and pathologic characteristics of SCC of the cervix
and LMVD
It is showed in logistic regression analysis that nuclear
maspin expression related to clinical stage of cervical
cancer and lymphatic metastasis (P \ 0.01, P \ 0.05,
respectively) (Table 4), while cytoplasmic maspin expres-
sion only related to the latter (P \ 0.05) (Table 5) without
association with clinical stage, invasive depth and histo-
logical grade (P [ 0.05). LMVD related to clinical stage,
lymphatic metastasis and histological grade (P \ 0.005,
P \ 0.05, P \ 0.05) but did not associate with invasive
Fig. 2 This figure shows maspin expression in CIN3. Both cytoplasm
and nucleus of squamous epithelial cells in CIN3 exhibited moderate
to strong maspin expression (HE9400)
Fig. 3 This figure shows maspin expression in SCC stage Ib. Both
cytoplasm and nucleus of cells in SCC stage Ib showed obviously
weaker staining of maspin than those of normal cervix and CIN3
Fig. 4 This figure shows maspin expression in SCC stage II.
Cytoplasm in cells of SCC stage II exhibited moderate expression
while nucleus of it showed weak maspin expression
Fig. 5 This figure shows maspin expression in lymph node free of
tumor metastasis. No maspin expressed in lymph node free of tumor
metastasis
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depth (P [ 0.05) (Table 6). It is showed in Spearman rank
correlation analysis that nuclear maspin expression was
negative related to clinical stage and LMVD (P \ 0.001,
P \ 0.005, respectively) whereas cytoplasmic maspin
expression was only negative related to LMVD
(P \ 0.005) having no association with clinical stage of
SCC (P [ 0.05). LMVD was positive related to clinical
stage (P \ 0.01) (Tables 7, 8).
Discussion
Carcinoma of the uterine cervix was one of the leading
ranks of malignant disease in female genital tract. World-
wide, cervical cancer is second only to breast cancer as the
most common cancer in terms of both incidence and
mortality rate. As we know, in cervical cancer, metastasis
through lymphatic vessels is the most common way to
Fig. 6 This figure shows maspin expression in tumor emboli of
lymph nodes. Both cytoplasm and nucleus showed extremely weak
maspin expression in tumor emboli of lymph nodes










nA nB RA RB
1 -2a 13 15 83.92 78.80
1 -3 13 15 83.92 55.60 *
1 -4 13 47 83.92 44.48 *
1 -5 13 13 83.92 12.19 *
2 -3 15 15 78.80 55.60 *
2 -4 15 47 78.80 44.48 *
2 -5 15 13 78.80 12.19 *
3 -4 15 47 55.60 44.48
3 -5 15 13 55.60 12.19 *
4 -5 47 13 44.48 12.19 *
Comparison of cytoplasmic maspin expressions between any two
groups using the Kruskal-Wallis rank sum test discovered SCC stage
Ib cytoplasmic maspin showed no significant difference with SCC
stage II but weaker than normal cervix and CIN3. Maspin expression
in cytoplasm of tumor emboli in lymph nodes was obviously weaker
than SCC stage II
* indicates P \ 0.05
a Study groups: 1, normal cervix; 2, CIN3; 3, SCC stage Ib; 4, SCC
stage II; 5, tumor emboli in lymph nodes










nA nB RA RB
1 22a 13 15 81.57 90.36
1 23 13 15 81.57 63.60
1 24 13 47 81.57 35.25 *
1 25 13 13 81.57 25.30 *
2 23 15 15 90.36 63.60 *
2 24 15 47 90.36 35.25 *
2 25 15 13 90.36 25.30 *
3 24 15 47 63.60 35.25 *
3 25 15 13 63.60 25.30 *
4 25 47 13 35.25 25.30
Comparison of nuclear maspin expression between any two groups
using the Kruskal-Wallis rank sum test discovered nuclear maspin
expression of CIN3 was little up-regulated than normal cervix and
then declined in SCC stage Ib. SCC stage II nuclear maspin was
obviously weaker than SCC stage Ib but showed no statistical sig-
nificance with tumor emboli in lymph nodes
* indicates P \ 0.05
a Study groups: 1, normal cervix; 2, CIN3; 3, SCC stage Ib; 4, SCC
stage II; 5, tumor emboli in lymph nodes
Fig. 7 This figure shows lymphatic microvessels around tumor tissue
of cervical cancer. Lymphatic microvessels stained with podoplanin
in SCC stage Ib mostly located in the area around the tumor
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spread out and is also a cardinal factor affecting prognosis
of patients. Birner et al. [26] discovered there had already
been lymphatic vessels involvement in 35.7 % of cases in
early stages of cervical cancer and the disease-free survival
rate for 5 years was obviously lower in the group with
lymphatic vessels involvement than the group without it
and there are lymph nodes metastasis in 65.7 % of patients
with lymphatic vessels involvement indicating that there is
a correlation between lymphatic vessels involvement and
lymph nodes metastasis. Therefore, close attention has
recently been paid to both the effect of lymphatic micro-
vessels on tumor lymphatic metastasis and the regulation of
lymphangiogenesis. Any tool allows predicting the poten-
tial for progression and metastasis in patients with cervical
cancer may be clinically valuable.
Maspin, a serine protease inhibitor, was originally
identified in normal human breast epithelial and myoepi-
thelial cell lines [2]. It has been widely proved that maspin
expressed in many kinds of human tissues and organs, such
as breast, prostate, gastrointestinal tract, endothelium of the
uterine, and trophocyte of the placenta. After Zou et al. [4]
first reported that maspin expression obviously descended
in invasive breast carcinoma, the same expression pattern
had been discovered in many other kinds of tumors such as
Table 4 Logistic regression analysis of nuclear maspin expression and clinical/pathologic characteristics of cervical cancer
Clinical/pathologic
parameter





Clinical stage 1 2.4459 0.6299 15.0785 0.0091
Invasive depth 1 -0.2774 0.5772 0.2310 0.6308
Lymphatic metastasis 1 2.3894 0.6636 12.9651 0.0183
Histological grade 1 0.6547 0.5473 1.4308 0.2316
It is showed in logistic regression analysis that nuclear maspin expression related to clinical stage of cervical cancer and lymphatic metastasis












Clinical stage 1 0.6617 0.5671 1.3614 0.2433
Invasive depth 1 -0.0608 0.5821 0.0109 0.9169
Lymphatic metastasis 1 2.2852 0.6448 12.5621 0.0104
Histological grade 1 -0.0194 0.5361 0.0013 0.9711
Logistic regression analysis shows that cytoplasmic maspin expression only related to lymphatic metastasis
Table 6 Logistic regression analysis of LMVD and clinical/pathologic characteristics of cervical cancer
Clinical/pathologic
parameter





Clinical stage 1 -1.7374 0.5909 8.6439 0.0033
Invasive depth 1 -0.3552 0.5765 0.3797 0.5378
Lymphatic metastasis 1 -2.4775 0.6536 14.3663 0.0127
Histological grade 1 -1.1024 0.5453 4.0874 0.0432
Logistic regression analysis shows that LMVD related to clinical stage, lymphatic metastasis and histological grade
Fig. 8 This figure shows lymphatic microvessels stained with
podoplanin were rare or even absent in the internal parts of tumor
in SCC stage II
378 Arch Gynecol Obstet (2014) 289:373–382
123
prostate cancer, renal cell carcinoma, oral cavity squamous
cancer, gastric carcinoma and colonic cancer [3, 5, 7, 27].
However, not all kinds of tumors support the above pattern.
Contrasted with the early research, maspin expression was
weak or even absent in normal ovarian tissue but it strongly
expressed in ovarian cancer [12]. Other studies showed that
maspin expression was positive related to tumor size and
histological grade but negative related to relapse free sur-
vival and total survival span [10, 16–18]. Some people
even took the viewpoint that maspin expression only
strengthened in invasive breast cancer of high histological
grade and maspin over expression means high risk of death
for patients without lymphatic metastasis [28]. These par-
adoxical results of different studies is intriguing and most
probably reflects the variation in pathogenesis of tumors in
different organs as well as sufficiently demonstrated the
complexity of maspin expression and its effect on tumor
progression and metastasis. Although the mechanism of
biological function of maspin is still unclear, it has been
demonstrated that maspin inhibits tumor cell motility,
invasion and metastasis as well as tumor angiogenesis [29].
These findings support the tumor suppression role of ma-
spin in tumor progression. But only a few studies have
mentioned maspin expression in the cervix.
Furthermore, it has been observed that even deeper
significance may exist in subcellular localization of ma-
spin. Maspin located mostly in cytoplasm in invasive tumor
while it expressed stronger in nucleus in benign or mild
malignant tumors [30, 31]. Subcellular location of maspin
expression may predict the different clinical types of
tumors and prognosis of patients [4, 18–20].
In our study, maspin expression is detected in both
cytoplasm and nucleus of normal cervix, CIN3, SCC and
tumor emboli in lymph nodes which obviously decreased
in the latter two groups (P \ 0.05) and showed the weakest
expression or even absence in tumor emboli in lymph
nodes. According to our result, maspin expression in cer-
vical cancer just like that in breast and prostate cancer and
support its tumor suppressor role.
Both cytoplasmic and nuclear maspin expressions of
SCC stage Ib were obviously weaker than normal cervix
and CIN3 (P \ 0.05). Diminished cytoplasmic maspin
expression is not identified in CIN3 compared with normal
squamous epithelium while nuclear maspin expression in
CIN3 was a little upregulated than both normal cervix and
SCC. The upregulation of nuclear maspin expression in
CIN3 may be a stress reaction to cancerigenic factors
in vivo or vitro or to an oncogene that will be or has
already been activated. As maspin has been proved a reg-
ulation target of gene p53 [32, 33] and maspin expression is
either negative related to p53 expression or increased with
the step-up of abnormal expression of it [34], maspin may
be the replacement or supplement for insufficient or even
lost function of anti-oncogene p53 as a secondary tumor
suppressor gene. Increased nuclear maspin expression in
CIN3 could be the earliest change happens when CIN3 or
carcinoma in situ will soon progress to invasive cancer. Xu
Cet al. [1] had discovered that maspin expression in
cytoplasm gradually descended in CIN3, micro-invasive
and invasive squamous cell carcinoma of the uterine cervix
and the level of cytoplasmic maspin expression in CIN3
adjacent to invasive cancer is lower than that in CIN3
without invasive carcinoma, but the nuclear maspin
expression has not been mentioned. Combined with our
study, we think it is the early event of tumor invasion that
maspin increased in nucleus while diminished in cytoplasm
in CIN3 and maspin plays a role in disease progression
from CIN3 to invasive squamous cervical carcinoma.
Squamous cell carcinoma stage II nuclear maspin
expression was obviously weaker than SCC stage Ib
(P \ 0.05) although cytoplasmic maspin expression
showed no significant difference between the two groups
(P [ 0.05). SCC stage II cytoplasmic maspin expression
Table 7 Spearman rank correlation analysis of nuclear maspin




















The first line of each cell is the correlation coefficient and the second
line is the P value
Spearman rank correlation analysis shows that nuclear maspin
expression was negatively related to clinical stage and LMVD
Table 8 Spearman rank correlation analysis of cytoplasmic maspin




















The first line of each cell is the correlation coefficient and the second
line is the P value
Spearman rank correlation analysis shows that cytoplasmic maspin
expression was negatively related to LMVD, which was positively
related to clinical stage
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was stronger than that of tumor emboli in lymph nodes
(P \ 0.05) while nuclear maspin expression was extremely
weak in both groups. If take the nuclear maspin expression
level of tumor emboli in metastatic lymph nodes as the
‘‘baseline’’ and draw the curve of nuclear maspin expres-
sion from normal cervix to metastatic carcinoma, it will
show a peak in CIN3 and then gradually dropped which
indicate that nuclear maspin first react to oncogenic factors
and then direct the change of maspin in cytoplasm.
Extremely weak SCC stage II nuclear maspin expression
demonstrated the exhaustion of tumor suppression effect of
maspin and increased potential for local invasive and
lymphatic metastasis in spite of the cytoplasmic maspin
expression was still maintained. Nuclear maspin expression
of both SCC stage II and tumor emboli in metastatic lymph
nodes were extremely weak and existed no statistical sig-
nificance not only support the above viewpoint but also
demonstrated the possibility that tumor cells in metastatic
lymph nodes come from the primary cancer sites of SCC.
As we know, microvasculature plays an important role
in the process of tumor invasion and metastasis. In cervical
cancer, metastasis through lymphatic vessels is the most
common way to spread out. Schoppmann et al. [35] have
discovered increased LMVD and lymphatic vessels
involvement had a relationship with axillary lymph nodes
metastasis when they used podoplanin to label lymphatic
microvessels in invasive breast carcinoma. In present
research, after labeling with podoplanin, the lymphatic
microvessels in cervical cancer were discovered mostly in
interstitial tissue and periphery of the tumor but rare or
even absent in the tumor tissue. LMVD in SCC stage Ib is
lower than that in SCC stage II with statistical significance
(P \ 0.05) demonstrating LMVD gradually increased with
the progression of SCC of cervix.
Some researchers have demonstrated that maspin
expression was negative related to tumor stage, histological
grade and depth of invasion [3–7]. Downregulated or
absent of maspin expression may signify the increased
potential for tumor metastasis and poor prognosis [6, 7, 9].
Our study shows that nuclear maspin expression had
inverse correlation with clinical stage (P \ 0.05) and
metastasis of lymph nodes (P \ 0.05), that is, the lower the
nuclear maspin expression, the later the clinical stage of
cervical cancer, and the metastasis of lymph nodes is more
likely to happen. As we know, lymphatic metastasis is still
an important factor for prognosis; our research could
indicate that nuclear maspin expression was significantly
related to tumor progression and metastasis of local lymph
nodes and has further significance in predicting pelvic
lymph nodes metastasis and prognosis of patients.
Invasive depth is another important factor for prognosis
of patients, although our research did not show any sta-
tistical significance in nuclear maspin expression between
the two groups that invasive depth is less than or equal to or
more than 1/2 of the whole layer, it disclosed from another
point that change of nuclear maspin expression is the early
event in tumor progression and metastasis. And now, the
clinical dividing of less than or equal to and more than 1/2
of the whole layer in invasive depth may be too rough to
detect the molecular biological change that happened in
cells of early stage in tumor progression. The differentia-
tion grade is also a factor affecting prognosis of patients.
Generally speaking, the poorer the differentiation grade is,
the worse the malignant grade and prognosis is. Our
research did not show there is a relationship between
nuclear maspin expression and cell differentiation could be
explained as neither maspin expression nor cell differen-
tiation grade is an independent factor that will affect the
progression of cervical cancer.
It has been showed in most studies that the formation of
newborn lymphatic vessels promoting the lymphatic
metastasis of tumors and the higher the LMVD is, the
easier the tumor cells go into the lymphatic system [36,
37]. Some studies also suggested that the area around
tumor is more suitable for development of lymphatic
microvessels and it is more likely lymphatic microvessels
of this area participate in the metastasis and spreading of
tumor cells [38]. It has also been proved in our research
that LMVD increased in periphery of the tumor while
obviously diminished intratumorally. LMVD was obvi-
ously higher in SCC stage II than in SCC stage Ib
(P \ 0.05) and the increase of LMVD was obviously
related to late clinical stage, lymph nodes metastasis and
poor differentiation grade (P \ 0.05). So local lymphatic
microvessels may develop important effect on lymphatic
metastasis in cervical cancer.
Although maspin has been proved to be related with the
decrease of density of tumor capillary in both breast and
colonic cancer [39, 40] and can inhibit the formation of
blood vessels in tumors [31, 41], few reports have men-
tioned the relationship between maspin expression and
lymphatic microvessels until now. It is generally thought,
primitive vein is the common origin of both blood and
lymphatic vessels. They differentiate under disparate reg-
ulation mechanisms. The homology is also manifested in
fact that they are both promoted by VEGF and inhibited by
classic angiostatin such as inhibin and platelet factor IV
[42]. But does maspin, which has the obvious inhibitory
effect on angiogenesis do the same on lymphangiogenesis?
The result of our study has demonstrated that maspin
expression both in cytoplasm and nucleus was obviously
negative related to LMVD (P \ 0.05) from which we
could predict that maspin plays an inverse impact on
lymphangiogenesis in the progression of squamous cell
carcinoma of the uterine cervix and in a certain degree, it
delays or even holds the metastasis of local lymph nodes.
380 Arch Gynecol Obstet (2014) 289:373–382
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But details about it still remain unclear and further evi-
dence is needed for making a decision.
In conclusion, subcellular location of maspin expression
could be a potentially useful marker to identify the pro-
gression and prognosis of patients in cervical cancer since
maspin expression correlated with clinical stage and lym-
phatic metastasis of the tumor. Maspin expression in both
cytoplasm and nucleus exists a negative relationship with
LMVD in cervical cancer support a role for maspin in
lymphangiogenesis and lymphatic metastasis.
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